Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy
Identifieur interne : 004661 ( Main/Exploration ); précédent : 004660; suivant : 004662Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy
Auteurs : Han-Cheng Wang [Taïwan] ; Yoloung Hsieh [Taïwan]Source :
- Movement Disorders [ 0885-3185 ] ; 2001-07.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Agonist, Apomorphine (administration & dosage), Butyrophenone derivatives, Case study, Chemotherapy, Dopamine receptor, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Haloperidol, Haloperidol (administration & dosage), Haloperidol (adverse effects), Human, Humans, Injections, Subcutaneous, Malignant syndrome, Neuroleptic, Neuroleptic Malignant Syndrome (drug therapy), Neurologic Examination (drug effects), Schizophrenia (drug therapy), Subcutaneous administration, Treatment, Trihexyphenidyl (administration & dosage), Trihexyphenidyl (adverse effects).
- MESH :
- chemical , administration & dosage : Apomorphine, Haloperidol, Trihexyphenidyl.
- chemical , adverse effects : Haloperidol, Trihexyphenidyl.
- drug effects : Neurologic Examination.
- drug therapy : Neuroleptic Malignant Syndrome, Schizophrenia.
- Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Injections, Subcutaneous.
Abstract
A 20‐year‐old psychiatric patient receiving haloperidol treatment developed acute‐onset fever, rigidity, and mental changes. Subcutaneous apomorphine was given alone for treatment. The patient had rapid clinical improvement after the treatment. Serial blood examinations showed decline and subsequent normalization of the creatine phosphokinase levels.
Url:
DOI: 10.1002/mds.1133
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001D60
- to stream Istex, to step Curation: 001D60
- to stream Istex, to step Checkpoint: 002E87
- to stream Main, to step Merge: 006B42
- to stream PascalFrancis, to step Corpus: 002962
- to stream PascalFrancis, to step Curation: 000359
- to stream PascalFrancis, to step Checkpoint: 002881
- to stream Main, to step Merge: 006D80
- to stream PubMed, to step Corpus: 003C90
- to stream PubMed, to step Curation: 003C90
- to stream PubMed, to step Checkpoint: 003C18
- to stream Ncbi, to step Merge: 000561
- to stream Ncbi, to step Curation: 000561
- to stream Ncbi, to step Checkpoint: 000561
- to stream Main, to step Merge: 006920
- to stream Main, to step Curation: 004661
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy</title><author><name sortKey="Wang, Han Heng" sort="Wang, Han Heng" uniqKey="Wang H" first="Han-Cheng" last="Wang">Han-Cheng Wang</name></author><author><name sortKey="Hsieh, Yoloung" sort="Hsieh, Yoloung" uniqKey="Hsieh Y" first="Yoloung" last="Hsieh">Yoloung Hsieh</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DF57C0FFD308C82DDCF23E23CF83808C744EA23D</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1133</idno><idno type="url">https://api.istex.fr/document/DF57C0FFD308C82DDCF23E23CF83808C744EA23D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001D60</idno><idno type="wicri:Area/Istex/Curation">001D60</idno><idno type="wicri:Area/Istex/Checkpoint">002E87</idno><idno type="wicri:doubleKey">0885-3185:2001:Wang H:treatment:of:neuroleptic</idno><idno type="wicri:Area/Main/Merge">006B42</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:01-0429779</idno><idno type="wicri:Area/PascalFrancis/Corpus">002962</idno><idno type="wicri:Area/PascalFrancis/Curation">000359</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002881</idno><idno type="wicri:doubleKey">0885-3185:2001:Wang H:treatment:of:neuroleptic</idno><idno type="wicri:Area/Main/Merge">006D80</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11481709</idno><idno type="wicri:Area/PubMed/Corpus">003C90</idno><idno type="wicri:Area/PubMed/Curation">003C90</idno><idno type="wicri:Area/PubMed/Checkpoint">003C18</idno><idno type="wicri:Area/Ncbi/Merge">000561</idno><idno type="wicri:Area/Ncbi/Curation">000561</idno><idno type="wicri:Area/Ncbi/Checkpoint">000561</idno><idno type="wicri:doubleKey">0885-3185:2001:Wang H:treatment:of:neuroleptic</idno><idno type="wicri:Area/Main/Merge">006920</idno><idno type="wicri:Area/Main/Curation">004661</idno><idno type="wicri:Area/Main/Exploration">004661</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy</title><author><name sortKey="Wang, Han Heng" sort="Wang, Han Heng" uniqKey="Wang H" first="Han-Cheng" last="Wang">Han-Cheng Wang</name><affiliation wicri:level="1"><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Neurology, Shin Kong Wu Ho‐Su Memorial Hospital, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Hsieh, Yoloung" sort="Hsieh, Yoloung" uniqKey="Hsieh Y" first="Yoloung" last="Hsieh">Yoloung Hsieh</name><affiliation wicri:level="1"><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Neurology, Shin Kong Wu Ho‐Su Memorial Hospital, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-07">2001-07</date><biblScope unit="vol">16</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="765">765</biblScope><biblScope unit="page" to="767">767</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DF57C0FFD308C82DDCF23E23CF83808C744EA23D</idno><idno type="DOI">10.1002/mds.1133</idno><idno type="ArticleID">MDS1133</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Agonist</term><term>Apomorphine (administration & dosage)</term><term>Butyrophenone derivatives</term><term>Case study</term><term>Chemotherapy</term><term>Dopamine receptor</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Haloperidol</term><term>Haloperidol (administration & dosage)</term><term>Haloperidol (adverse effects)</term><term>Human</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Malignant syndrome</term><term>Neuroleptic</term><term>Neuroleptic Malignant Syndrome (drug therapy)</term><term>Neurologic Examination (drug effects)</term><term>Schizophrenia (drug therapy)</term><term>Subcutaneous administration</term><term>Treatment</term><term>Trihexyphenidyl (administration & dosage)</term><term>Trihexyphenidyl (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Apomorphine</term><term>Haloperidol</term><term>Trihexyphenidyl</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Haloperidol</term><term>Trihexyphenidyl</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neuroleptic Malignant Syndrome</term><term>Schizophrenia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Apomorphine</term><term>Butyrophénone dérivé</term><term>Chimiothérapie</term><term>Etude cas</term><term>Halopéridol</term><term>Homme</term><term>Neuroleptique</term><term>Récepteur dopaminergique</term><term>Syndrome malin</term><term>Traitement</term><term>Voie souscutanée</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A 20‐year‐old psychiatric patient receiving haloperidol treatment developed acute‐onset fever, rigidity, and mental changes. Subcutaneous apomorphine was given alone for treatment. The patient had rapid clinical improvement after the treatment. Serial blood examinations showed decline and subsequent normalization of the creatine phosphokinase levels.</div></front></TEI><affiliations><list><country><li>Taïwan</li></country></list><tree><country name="Taïwan"><noRegion><name sortKey="Wang, Han Heng" sort="Wang, Han Heng" uniqKey="Wang H" first="Han-Cheng" last="Wang">Han-Cheng Wang</name></noRegion><name sortKey="Hsieh, Yoloung" sort="Hsieh, Yoloung" uniqKey="Hsieh Y" first="Yoloung" last="Hsieh">Yoloung Hsieh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004661 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004661 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DF57C0FFD308C82DDCF23E23CF83808C744EA23D
|texte= Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy
}}
| This area was generated with Dilib version V0.6.23. |  |